The
ASH posed a question today: How
would you treat MDS that has not responded to azacitidine?
Well,
I don’t know. But the linked reference shed some light on the matter…
They
also sent a link to their September
Newsletter which had all sorts of snippets. Perhaps a little too much
on the clinical side for me? But I need
to be aware of what the end users of my efforts want, don’t I?
No comments:
Post a Comment